Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 472
- sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- conditions
- Schizophrenia
- interventions
- DRUG: Xanomeline/Trospium Chloride; DRUG: Placebo
- start date
- 2026-08-20
- start date type
- ACTUAL
- primary completion date
- 2029-03-03
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07686263
- Published
- Jul 7, 2026
- Updated
- Sep 28, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07686263
- Categories
- Schizophrenia
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials